Abstract:OBJECTIVE:Genome-wide association studies have linked variants of fat mass and obesity-associated protein (FTO) to obesity. However, the molecular function of FTO remains unclear. In this study, we sought to investigate the potential effects of FTO in modulating cholesterol deposition in macrophage foam cells, as well as whether FTO exerts antiatherosclerotic properties in apolipoprotein E-deficient mice. METHOD AND RESULTS:We transfected RAW264.7 cells with plasmids encoding a wild-type or mutant FTO gene (I367F). The upregulation of FTO markedly attenuated cholesterol ester accumulation in macrophages loaded with oxidized LDL, whereas the downregulation of FTO reversed this effect. Moreover, FTO attenuated the mRNA and protein expression of a scavenger receptor, CD36, which was accompanied by the decline of peroxisome proliferator-activated receptor γ protein. In addition, FTO enhanced the phosphorylation of AMP-activated protein kinase (AMPK)α and acetyl-CoA carboxylase, which was effectively suppressed by FTO small interfering RNA. Pretreatment with compound C or transfection with a dominant-negative AMPKα blocked the FTO-mediated upregulation of ATP-binding cassette transporter A1 and ATP-binding cassette transporter G1. Furthermore, FTO suppressed IL-1β secretion independent of the activation of the nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 inflammasome. In-vivo experiments were performed using apolipoprotein E-deficient mice that were infected with adeno-associated virus serotype 9-derived vectors encoding a wild-type or mutant FTO gene. FTO overexpression prevented the formation of atherosclerotic plaques and markedly reduced the content of plasma total cholesterol and LDL cholesterol. Notably, the antiatherosclerotic properties of FTO were observed only in male mice. CONCLUSION:We propose that the FTO-dependent control of cholesterol deposition may provide avenues for the treatment of atherosclerosis.

Downregulated fat mass and obesity-associated protein inhibits bone resorption and osteoclastogenesis by nuclear factor-kappa B inactivation

Alpinetin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss by Modulating NFATc1 Transcription and Lysosomal Function

FATP2 Regulates Osteoclastogenesis by Increasing Lipid Metabolism and ROS Production.

The GDF11-FTO-PPARγ Axis Controls the Shift of Osteoporotic MSC Fate to Adipocyte and Inhibits Bone Formation During Osteoporosis.

FTO regulates osteoclast development by modulating the proliferation and apoptosis of osteoclast precursors in inflammatory conditions

Administration of SB239063 Ameliorates Ovariectomy-Induced Bone Loss Via Suppressing Osteoclastogenesis in Mice

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

Fat mass and obesity-associated protein attenuates lipid accumulation in macrophage foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice.

The m6A demethylase FTO promotes the osteogenesis of mesenchymal stem cells by downregulating PPARG

RNA N6-methyladenosine demethylase FTO promotes osteoporosis through demethylating Runx2 mRNA and inhibiting osteogenic differentiation

Fat Mass and Obesity-Associated (FTO) Stimulates Osteogenic Differentiation of C3H10T1/2 Cells by Inducing Mild Endoplasmic Reticulum Stress via a Positive Feedback Loop with p-AMPK

The RNA demethylase FTO is required for maintenance of bone mass and functions to protect osteoblasts from genotoxic damage

FTO inhibits UPRmt-induced apoptosis by activating JAK2/STAT3 pathway and reducing m6A level in adipocytes

Trimethylamine-N-Oxide Promotes Osteoclast Differentiation and Bone Loss via Activating ROS-Dependent NF-B Signaling Pathway

Trimethylamine-N-Oxide Promotes Osteoclast Differentiation and Bone Loss via Activating ROS-Dependent NF-κB Signaling Pathway

FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis

FTO is a Transcriptional Repressor to Auto-Regulate Its Own Gene and Potentially Associated with Homeostasis of Body Weight.

RNA N6‐methyladenosine demethylase FTO inhibits glucocorticoid‐induced osteoblast differentiation and function in bone marrow mesenchymal stem cells

FTO is Required for Myogenesis by Positively Regulating Mtor-Pgc-1α Pathway-Mediated Mitochondria Biogenesis

TAZ Inhibits Osteoclastogenesis by Attenuating TAK1/NF-κB Signaling

Downregulation of Fat Mass and Obesity Associated (FTO) Promotes the Progression of Intrahepatic Cholangiocarcinoma